3-amino-2,4-dimethoxy-6-methylpyridine | 90197-37-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-amino-2,4-dimethoxy-6-methylpyridine
• 英文别名: 2,4-Dimethoxy-6-methylpyridin-3-amine
• CAS: 90197-37-8
• 化学式: C₈H₁₂N₂O₂
• 分子量: 168.195
• InChiKey: OWCLZUSYLASQLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  57.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-amino-2,4-dimethoxy-6-methylpyridine 在 N,N-二甲基苯胺 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 1-Cycloheptyl-3-(2,4-dimethoxy-6-methyl-pyridin-3-yl)-1-[4-(4-fluoro-phenoxy)-benzyl]-urea
  参考文献：
  名称：

  Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase. 3. Discovery of a Novel Series of N-Alkyl-N-[(fluorophenoxy)benzyl]-N‘-arylureas with Weak Toxicological Effects on Adrenal Glands

  摘要：

  A series of N-alkyl-N-[(fluorophenoxy)benzyl] -N'-arylureas were prepared and evaluated for their ability to inhibit intestinal acyl-CoA:cholesterol O-acyltransferase and to inhibit accumulation of cholesteryl esters in macrophages in vitro. In vivo hypocholesterolemic activity was assessed in cholesterol-fed rats by oral administration as a dietary admixture and/or by gavage in a PEG400 vehicle. Modification of the alkyl substituent on the N'-aryl moiety and on the urea nitrogen significantly influenced macrophage assay in vitro. Toxicological study revealed a distinct relationship between macrophage assay and the toxicity observed in adrenal glands of rabbits treated with representatives of this series of compounds. Investigations utilizing the macrophage assay as an indicator for adrenal toxicity led to the identification of compounds 1g (FR190809) and 1k (FR186485, or FR195249 as its hydrochloride salt) as potent, nonadrenotoxic, orally efficacious ACAT inhibitors irrespective of the administration method.

  DOI：

  10.1021/jm980399q
• 作为产物：
  描述：

  2,4-二氯-6-甲基-3-硝基吡啶 在 palladium on activated charcoal 氢气 作用下， 以 1,4-二氧六环 、 甲醇 、 乙腈 为溶剂， 80.0 ℃ 、101.33 kPa 条件下， 反应 10.5h， 生成 3-amino-2,4-dimethoxy-6-methylpyridine
  参考文献：
  名称：

  Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase. 3. Discovery of a Novel Series of N-Alkyl-N-[(fluorophenoxy)benzyl]-N‘-arylureas with Weak Toxicological Effects on Adrenal Glands

  摘要：

  A series of N-alkyl-N-[(fluorophenoxy)benzyl] -N'-arylureas were prepared and evaluated for their ability to inhibit intestinal acyl-CoA:cholesterol O-acyltransferase and to inhibit accumulation of cholesteryl esters in macrophages in vitro. In vivo hypocholesterolemic activity was assessed in cholesterol-fed rats by oral administration as a dietary admixture and/or by gavage in a PEG400 vehicle. Modification of the alkyl substituent on the N'-aryl moiety and on the urea nitrogen significantly influenced macrophage assay in vitro. Toxicological study revealed a distinct relationship between macrophage assay and the toxicity observed in adrenal glands of rabbits treated with representatives of this series of compounds. Investigations utilizing the macrophage assay as an indicator for adrenal toxicity led to the identification of compounds 1g (FR190809) and 1k (FR186485, or FR195249 as its hydrochloride salt) as potent, nonadrenotoxic, orally efficacious ACAT inhibitors irrespective of the administration method.

  DOI：

  10.1021/jm980399q

文献信息

• Novel cyclic diamine compounds and medicine containing the same
  申请人：Kowa Company, Ltd.

  公开号：US20040038987A1

  公开（公告）日：2004-02-26

  The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same. The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. 1 (In the formula, 2 is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group where Ar is an optionally substituted aryl group; X is —NH—, oxygen atom or sulfur atom; Y is —NR 1 —, oxygen atom, sulfur atom, sulfoxide or sulfone; Z is a single bond or —NR 2 —; R 1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; R 2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; l is an integer of from 0 to 15; m is an integer of 2 or 3; and n is an integer of from 0 to 3). The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).

  本发明提供了新颖的环状二胺化合物以及含有该化合物的药物组合物。本发明涉及由式(I)表示的化合物或其盐或溶剂化合物。(在该式中，2是苯、吡啶、环己烷或萘的可选择取代的二价残基，或者是Ar为可选择取代芳基的乙烯基；X为—NH—、氧原子或硫原子；Y为—NR1—、氧原子、硫原子、亚砜或砜；Z为单键或—NR2—；R1为氢原子、可选择取代的较低烷基、可选择取代的芳基或可选择取代的硅烷较低烷基；R2为氢原子、可选择取代的较低烷基、可选择取代的芳基或可选择取代的硅烷较低烷基；l为0到15的整数；m为2或3的整数；n为0到3的整数)。本发明的化合物可用作药物组合物，特别是作为酰辅酶A胆固醇酰基转移酶(ACAT)的抑制剂。
• Discovery of Clinical Candidate 2-(4-(2-((1<i>H</i>-Benzo[<i>d</i>]imidazol-2-yl)thio)ethyl)piperazin-1-yl)-<i>N</i>-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol <i>O</i>-Acyltransferase-1 Inhibitor
  作者：Kimiyuki Shibuya、Katsumi Kawamine、Chiyoka Ozaki、Tadaaki Ohgiya、Toshiyuki Edano、Yasunobu Yoshinaka、Yoshihiko Tsunenari

  DOI：10.1021/acs.jmedchem.8b01256

  日期：2018.12.13

  azin-1-yl)-N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide hydrochloride (K-604, 2) has been identified as an aqueous-soluble potent inhibitor of human acyl-coenzyme A:cholesterol O-acyltransferase (ACAT, also known as SOAT)-1 that exhibits 229-fold selectivity for human ACAT-1 over human ACAT-2. In our molecular design, the insertion of a piperazine unit in place of a 6-methylene chain in the

  2-（4-（2-（（（1 H-苯并[ d ]咪唑-2-基]硫代]乙基]哌嗪-1-基] -N-（6-甲基-2,4-双（甲硫基）]吡啶-3-基）乙酰胺盐酸盐（K-604，2）已被确定为人类酰基辅酶A的水性可溶强效抑制剂：胆固醇ö -acyltransferase（ACAT，也称为这项方案）-1表现出229倍对人ACAT-1的选择性高于对人ACAT-2的选择性。在我们的分子设计中，在头部（吡啶基乙酰胺）和尾部（苯并咪唑）之间的连接基中插入哌嗪单元代替6-亚甲基链导致水溶解度显着提高（最高19 mg / mL） pH 1.2时）和口服吸收的显着改善（C max为2为1100倍比的更高1与先前选择的化合物，相比于禁食的狗）1。在确保药理作用和安全性之后，我们指定2个临床候选药物，命名为K-604。考虑到ACAT抑制剂在过去的临床试验中的治疗结果，我们认为K-604将可用于治疗涉及ACAT-1过表达的不治之症。
• NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME
  申请人：Kowa Co., Ltd.

  公开号：EP0987254B1

  公开（公告）日：2004-12-22
• UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0784612A1

  公开（公告）日：1997-07-23
• US6969711B2
  申请人：——

  公开号：US6969711B2

  公开（公告）日：2005-11-29